Objective: To systemically evaluate the safety and efficacy of Shenqi Fuzheng injection combined with GP treatment for non-small cell lung cancer. Method: Wanfang

CNKI

CBM

VIP and US national library of medicine were searched for the clinical randomized controlled trials of Shenqi Fuzheng injection combined with GP treatment for non-small cell lung cancer from the database establishment to August 2015.The articles were selected according to inclusion and exclusion criteria

and the data extraction and quality assessment were done for the included studies

and then Revman 5.3 software was used for Meta-analysis. Result: The 12 randomized controlled trials were included in the systematic review

covering a total of 928 patients. All of them were low-quality studies with Jadad score ≤3. Meta analysis showed that:compared with GP treatment alone

Shenqi Fuzheng injection combined with GP treatment for non-small cell lung cancer could significantly increase the efficiency[OR=1.72

95% CI (1.32

2.25)

P<0.0001]

improve the quality of life for patients[OR=3.35

95% CI (2.50

4.49)

P<0.00001]

reduce leucopenia[OR=0.30

95% CI (0.21

0.42)

P<0.00001]and hemoglobin decline[OR=0.37

95% CI (0.22

0.62)

P=0.0002]

and reduce gastrointestinal reactions[OR=0.47

95% CI (0.33

0.68)

P<0.0001]

with statistically significant difference. Conclusion: Shenqi Fuzheng injection combined with GP treatment for non-small cell lung cancer can significantly improve the efficiency and quality of life for patients and reduce side effects of chemotherapy. However

the existing small-sample randomized controlled trials have low methodological and reporting quality

so further rigorous clinical trials with high quality and large sample are still required for validation.